What is the price of Eli Lilly and Company today?

As of October 31, 2026, the price of Eli Lilly and Company is $1,417.54, up 3.19% from the previous close.

What is the all-time high of Eli Lilly and Company?

The highest price for Eli Lilly and Company in our data, which starts in November 2006, is $1,449.68, reached on October 30, 2026. At $1,417.54, the latest price is 2.22% below it.

How much has Eli Lilly and Company gained this year?

Eli Lilly and Company is up 31.90% so far in 2026: it closed 2025 at $1,074.68 and is at $1,417.54 now.

How volatile is Eli Lilly and Company?

Over the past year, Eli Lilly and Company had an annualised volatility of 35.20%, based on daily closes. Its deepest fall from a high in that time was 23.31%, from November 25, 2025 to April 29, 2026. Its beta against the S&P 500 was 0.24.

What was the biggest price drop for Eli Lilly and Company?

The deepest fall in our weekly price history since November 2006 was 53.80%, from a high in the week of April 16, 2007 to a low in the week of March 2, 2009. The price regained that high in the week of June 16, 2014.

Which month has historically been best for Eli Lilly and Company?

Since 2015, June has had the highest average return for Eli Lilly and Company (+5.99%, up in 11 of 12 years) and September the lowest (-0.74%, up in 7 of 12 years). Past seasonal patterns do not predict future returns.

stock · yahoo

Eli Lilly and Company

LLY

$1,417.54

▲ 43.84 (3.19%)

polled

Below: live stock price for Eli Lilly and Company (LLY), a 1-year chart, 8 indicators (RSI, MACD, Bollinger, MA, EMA, Stochastic, ATR, Volume), and a compare mode. Add to your portfolio, star to your watchlist, or set a price alert in one place.

Eli Lilly and Company (LLY) is a Healthcare company based in United States. Operating in Drug Manufacturers - General, it employs about 50,000 people. Over the past year LLY traded between 850.51 and 1,449.68 USD. Trailing P/E sits near 46.01 on a market cap of about 1.26T USD. It currently yields 0.49% in dividends.

Day

+3.19%

+43.84

Week

+11.31%

+144.08

Month

+23.28%

+267.69

Year

+64.28%

+554.68

Prev close: $1,373.70
Volume (24h): $7.13B
Market cap: $1.26T
Currency: USD

Score

57/ 100 · Mixed

Coverage: 7/7

Value22
Quality100
Momentum72
Growth65
Risk67
Dividend52
Liquidity24

Composite of public market data. Informational only — not investment advice.

Trend projection

Where the recent trend points if it continues.

UptrendFit 13%Pace +0.11% per bar

+5 bars+20 bars+60 bars+120 bars

+5 bars: 1,423.41
+20 bars: 1,431.55
+60 bars: 1,434.71
+120 bars: 1,434.83

Linear-regression continuation — not a prediction, not investment advice. ±1σ ≈ 68% range · ±2σ ≈ 95% range: 1σ ≈ ±1.99% per bar.

Interpretation

Composite signals look mixed. Strength: quality with weakness: valuation. Price sits near the upper third of the recent range, trend is sloping upward.

Descriptive observation — not investment advice.

Score breakdown

Raw values behind each pillar so you can see what the composite is reading.

Value
22/100
Value looks fragile — driven by P/E (46.01).
P/E:46.01P/B:31.37PEG:1.36
Quality
100/100
Quality looks strong — driven by ROE (86.02%).
ROE:86.02%ROA:21.06%Profit margin:31.90%Gross margin:83.63%
Momentum
72/100
Momentum looks solid — driven by 52w change (58.11%).
52w change:58.11%
Growth
65/100
Growth looks solid — driven by Revenue growth (38.60%).
Revenue growth:38.60%Earnings growth:16.30%
Risk
67/100
Risk looks solid — driven by Debt / equity (122.93).
Beta:0.45Debt / equity:122.93Short interest:0.78%
Dividend
52/100
Dividend looks mixed — driven by Payout ratio (21.71%).
Dividend yield:0.49%Payout ratio:21.71%
Liquidity
24/100
Liquidity looks fragile — driven by Current ratio (1.39).
Current ratio:1.39Quick ratio:0.64

Derived from public market data — informational, not investment advice.

Price report

How this asset has actually moved over the last 252 days.

Position in range95%

812.25 low1,449.68 high

Where the price sits between the window low and high.

Volatility (annualised): 35.2%
Max drawdown: -23.3%
Below period high: -2.2%
Best day: +10.33%
Worst day: -7.79%
Up days: 51%
Current streak: 5 up
Typical day swing: 2.9%
Volume vs average: +9%

Descriptive statistics over past prices — not a forecast and not investment advice.

Reference levels

Fibonacci retracements and extensions across the recent range.

60 bars

Reference only — not investment advice.

These coordinates describe past-trade clustering, not where to buy or sell. Do your own research before any trade.

Next level above

1,541.18 USD+8.72%

Fib +27.2% extension

Next level below

1,370.29 USD-3.33%

Fib 23.6% retracement

Levels derived from: 1,449.68 high → 1,113.29 low · 60 bars

Resistance
Fib +161.8% extension
not reached
1,993.96 USD
+40.66% from current
Resistance
Fib +100% extension
not reached
1,786.07 USD
+26.00% from current
Resistance
Fib +61.8% extension
not reached
1,657.57 USD
+16.93% from current
Resistance
Fib +27.2% extension
not reached
1,541.18 USD
+8.72% from current
Current
1,417.54 USD
Support
Fib 23.6% retracementNearest
tested 1×
1,370.29 USD
-3.33% from current
Support
Fib 38.2% retracement
tested 1×
1,321.18 USD
-6.80% from current
Support
Fib 50% midpoint
tested 7×
1,281.48 USD
-9.60% from current
Support
Fib 61.8% retracement
tested 6×
1,241.79 USD
-12.40% from current
Support
Fib 78.6% retracement
tested 19×
1,185.28 USD
-16.38% from current
Support
Fib −27.2% extension
not reached
1,021.79 USD
-27.92% from current
Support
Fib −61.8% extension
not reached
905.4011 USD
-36.13% from current
Support
Fib −100% extension
not reached
776.9001 USD
-45.19% from current

How to read this

We take the highest and lowest price of the last 60 bars and cut the gap between them at the classic Fibonacci ratios (23.6%, 38.2%, 50%, 61.8%, 78.6%), plus extensions beyond both ends.

“Tested N×” counts how many of those 60 bars actually traded through the level. A level price has crossed many times is one the market has repeatedly agreed on; a level at 0 is pure geometry the price has never reached.

This is a map of where trading has already happened — not a forecast and not a signal. Price moves through these levels all the time.

Financials

52w high: $1,449.68
52w low: $850.51
52w change: 58.11%
Day high: $1,449.68
Day low: $1,409.00
P/E (TTM): 46.01
Forward P/E: 28.72
PEG: 1.36
Price / Book: 31.37
Beta (5Y): 0.45
Enterprise value: 1.31T
EV / Revenue: 15.12
EV / EBITDA: 28.12
EPS (TTM): $30.81
Forward EPS: $49.36
Dividend yield: 0.49%
Dividend rate: $6.92
Payout ratio: 21.71%
Revenue (TTM): 86.46B
EBITDA: 46.49B
Free cash flow: 9.34B
Total cash: 4.89B
Total debt: 49.5B
Debt / Equity: 122.93
Current ratio: 1.39
Quick ratio: 0.64
Profit margin: 31.90%
Gross margin: 83.63%
Return on assets: 21.06%
Return on equity: 86.02%
Shares outstanding: 890.75M
Float: 888.34M

Sector: HealthcareIndustry: Drug Manufacturers - GeneralHQ: United StatesEmployees: 50Kwww.lilly.com

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss; Olumiant; Omvoh; and Taltz. Further, it provides Emgality for migraine prevention and episodic cluster headache; and Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron; strategic collaboration with Ascidian Therapeutics for development of therapies for undisclosed monogenic kidney diseases; BioArctic AB (publ) for new treatment; QurCan Therapeutics Inc for development of PLNP-enabled genetic medicine therapeutics for the treatment of central nervous system and peripheral nervous system; and Abbisko Therapeutics for discovery and development of medicines across multiple targets. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Analyst & Risk

Consensus

Analysts' consensus via Yahoo Finance — not investment advice.

Analysts: positive

Mean rating1.61 / 5

Analysts29

Next earnings2026-10-29

Very positive: 6Positive: 20Neutral: 3Negative: 1Very negative: 1

Analyst price target

$1,403.64

Mean target · 29 analysts

-1.0%

mean target vs. price

Low $930.00Now $1,417.54High $1,650.00

Beta (vs S&P 500): 0.45; very stable
52-week change: 58.11%
Short % of float: 0.78%
Short ratio (days): 3
Debt / Equity: 122.93; very high leverage
Current ratio: 1.39
Quick ratio: 0.64
ROE: 86.02%
ROA: 21.06%
PEG ratio: 1.36
EV / Revenue: 15.12
EV / EBITDA: 28.12
Revenue growth: 38.60%
Earnings growth: 16.30%
EBITDA: 46.49B
Free cash flow: 9.34B
Total cash: 4.89B
Total debt: 49.5B
Insider holdings: 0.16%
Institutional: 85.47%

Recent rating changes

2026-10-31UBSBuy → Buymain
2026-10-30JP MorganOverweight → Overweightmain
2026-10-30CitigroupBuy → Buymain
2026-10-30ScotiabankSector Outperform → Sector Outperformmain
2026-10-30Morgan StanleyOverweight → Overweightmain
2026-10-30Wells FargoOverweight → Overweightmain
2026-10-30Truist SecuritiesBuy → Buyreit
2026-10-30RBC CapitalOutperform → Outperformmain

Financial documents